Navigation Links
K-State researcher, collaborators study virulence of pandemic H1N1 virus
Date:7/30/2009

Laboratory studies at Kansas State University and the work of a K-State researcher are making headway in the effort to control the pandemic H1N1 virus.

Juergen Richt is a Regents Distinguished Professor at K-State's College of Veterinary Medicine and is a Kansas Bioscience Authority Eminent Scholar. His work at K-State and with outside collaborators is revealing the characteristics of the pandemic H1N1 virus.

Richt is among the K-State researchers who study zoonotic disease -- those that can be transmitted from animals to humans and vice versa. Zoonotic diseases will be a focus of the National Agro and Bio-Defense Facility that has been designated for Manhattan.

"Our strength at K-State is that we are very familiar with zoonotic diseases and we can contribute by working on models for animal and human diseases," Richt said. "This expertise is very critical now that an agent causing a pandemic flu in humans most likely originated in animal populations."

At K-State, Richt is leading in vitro research to develop better testing tools, creating a "diagnostic arsenal" if H1N1 were to spread to swine populations. Richt said they are developing diagnostic tools for the direct detection of the virus by finding nucleic acids or other parts of the virus in a sample, as well as tools for indirect detection. The latter approach is done by creating diagnostics that detect antibodies produced by animals infected with the virus.

"We do this work to protect the pig industry in case the virus would jump into the swine population," Richt said.

His work with outside collaborators is testing the virulence of pandemic H1N1 in animal models. In pigs, Richt and his fellow researchers found that pandemic H1N1 does infect pigs and transmits between the animals but is not fatal.

"Its important to know the clinical and pathological effects this virus has on pigs," Richt said. "It is also important to perform these experiments
'/>"/>

Contact: Juergen Richt
jricht@k-state.edu
785-532-4401
Kansas State University
Source:Eurekalert  

Page: 1 2

Related biology news :

1. K-State plant pathologists develop online teaching modules used globally
2. Researchers from around the globe coming to K-State June 21 for workshop on Fusarium fungus
3. K-State host to workshop on rapid methods to detect microorganisms in food
4. K-State researcher finds 1918 flu resulted in current lineage of H1N1 swine influenza viruses
5. K-State using Second Life island to help high school students learn earth science
6. K-State researchers work with university in Ghana to create biofuels from native tree seeds
7. K-State researchers help Epitopix license the United States first E. coli O157 vaccine for cattle
8. K-State biologist collaborating with researchers in Africa on grassland sustainability, biodiversity
9. Researchers to use K-States BSL-3 Lab for $1 million study of fungus threatening wheat crops
10. K-State research: Freshwater pollution costs US at least $4.3 billion a year
11. K-State professors USDA research shows mad cow disease also caused by genetic mutation

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
K-State researcher, collaborators study virulence of pandemic H1N1 virus
K-State researcher, collaborators study virulence of pandemic H1N1 virus
(Date:11/24/2009)...crets of the earth,s history locked in its icy dep...e information on the environments that have been s...Now, a team of researchers from nine institutions ...0 million dollars by the National Science Foundati...lly. These scientists will drill through the West ...
(Date:11/23/2009)... strain of the deadly superbug MRSAan infection-ca...sposes a far greater health threat than previously...ding to a study in the December issue of Emerging...ly picked up in fitness centers, schools, and othe...en of MRSA within hospitals, the report found. , ...
(Date:11/23/2009)...that a common oral bacterium may exacerbate autoim..., "Unique Lipids from a Common Human Bacterium Rep...ncing Autoimmunity," appears in the December 2009 ...Multiple sclerosis (MS), a disease where the immun...s nearly 1 in 700 people in the United States. Pa...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 1OAG Releases Prototype for Pandemic Disease Planning and Management 56336 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 3Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 1Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 2Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 3Making bacteria make useful proteins 13871 1
...essing their children, at least among side-blotche...States. Researchers at the University of Californi...d lizards are able to induce different color patte... "dressing" their progeny in patterns they will we...ence gives her progeny the patterns most likely to...
...n genetic factors and certain adverse events relat...in the July 15th issue of The Journal of Infectiou...tions for predicting adverse events from other liv...ts has been one of the greatest successes of moder...he world is considered by some to be the crowning ...
...finding new drugs to fight MRSA, cancers and other...isation announced that its fungal collection will ...BI houses one of the world’s largest genetic resou...strains, including Fleming’s original penicillin p...ersity of Strathclyde’s Institute for Drug Researc...
Other Biology News:Study shows lizard moms dress their children for success 2Study shows lizard moms dress their children for success 3Study shows lizard moms dress their children for success 4Genetic factors are linked to fever following smallpox vaccination 2Could fungal collection hold the key to new life-saving drugs? 2
(Date:11/24/2009)... The New York investment bank KTA Capital,s cli...d an AU$6.7 mil convertible note private placement...lacement was arranged by KTA Capital as Neuren,s e... New York (PRWEB) November 23, 2009 ...pital, LLC ("KTA Capital") has announced...
(Date:11/24/2009)...IS, Nov. 24 Sigma-Aldric...at the NASDAQ OMX conference on Tuesday, December ...rested parties may listen via live audio broadcast...tor.sig m a a ldrich.com/ . Users can click ...About Sigma-Aldrich: Sigma-Aldrich is a leading ...
(Date:11/24/2009)...TEO, Calif., Nov. 24 Neu... company focused on developing and commercializing...that Anthony DiTonno, President and Chief Executiv...ual Piper Jaffray Health Care Conference, to be he... in New York, New York. ,, Mr. DiTonno and Ste...
(Date:11/24/2009)...ary efficacy endpoint has been met for patients wi...cer, , QUEBEC CITY, Nov. 24 /PRNewswire-First...: AEZ) (the "Company"), a global biopharmaceutical..., today announced positive efficacy data from a Ph...njugate, AEZS-108 (formerly AN-152), in patients w...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...iated a Phase II study of R1507 ...ark, December 20 Genmab A/S,(OMX: GEN) announced ...e II,clinical study of R1507 for the treatment of ...y was created by Genmab under the company,s,agreem...igger a milestone,payment to Genmab of USD 500,000...
... a,drug and diagnostic discovery company, announce... to initiate a Phase 2 clinical trial of its,thera...mer,s disease. EHT,0202 is a compound, with a nove... memory and neuronal loss., This will be the firs...a multi-center, double-blind trial, in which 135 p...
...; Looks to Build Upon 2007 ...scoring its continued commitment,to advancing acce...he Avon,Foundation today announced the 2008 Avon W... in Avon Walk history, the series will expand into...mentum of a record-breaking,2007 Avon Walk season....
Other Biology Technology:Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 3ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 4Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3
RABBIT (BABY) COMPLEMENT LYOPHILISED from AbD Serotec
Rabbit Anti-Human ZO-1 Antibody, Unconjugated from Lab Vision
Mouse Anti-Human Myeloid Marker Monoclonal Antibody, Unconjugated, Clone BM-1 from Santa Cruz Biotechnology, Inc.
5x C'GATE STOCK STABILIZING REAGENT from AbD Serotec
Biology Products: